AIIMS Delhi Ph.D. Admission 2026
Entrance Examination – January 2026 Session
š¢ All India Institute of Medical Sciences (AIIMS), New Delhi, an Institute of National Importance (INI), has released the REVISED SCHEDULE for the Ph.D. Program Entrance Examination (Jan 2026).
š Revised Important Dates
| Event | Date |
|---|---|
| Online Registration Closing Date | 06th Feb 2026 (upto 05:00 pm) |
| Status of Application & Rejection | 11th Feb 2026 (upto 05:00 pm) |
| Uploading of Admit Card | 14th Feb 2026 (upto 05:00 pm) |
| Date of Examination | 17th Feb 2026 (Tuesday) |
| Expected Declaration of Result | 26th Feb 2026 (Thursday) |
| Departmental Assessment | 05th & 06th March 2026 |
| Final Result | 13th March 2026 (Friday) |
| Last Date for Joining | 31st March 2026 (Tuesday) |
š Quick Overview
Total Seats
77
FA Seats
38
OF Seats
39
Departments
30
Exam Mode
CBT (Online)
Duration
90 Mins
š° Application Fee
| General/OBC | ā¹2,000 + charges |
| SC/ST/EWS | ā¹1,600 + charges |
| PwBD | Nil |
š Seat Distribution
| Dept | FA | OF | Total |
|---|---|---|---|
| Anaesthesiology | 01 | 00 | 01 |
| Anatomy | 05 | 02 | 07 |
| Biochemistry | 02 | 06 | 08 |
| Biophysics | 02 | 03 | 05 |
| Biotechnology | 00 | 01 | 01 |
| Cardiology | 01 | 00 | 01 |
| Dermatology | 01 | 00 | 01 |
| Emergency Med | 00 | 01 | 01 |
| Endocrinology | 01 | 01 | 02 |
| Forensic Med | 01 | 01 | 02 |
| Gastroenterology | 02 | 01 | 03 |
| Lab Medicine | 01 | 01 | 02 |
| Lab Oncology | 00 | 02 | 02 |
| Med Oncology | 00 | 03 | 03 |
| Microbiology | 01 | 02 | 03 |
| Neurology | 02 | 01 | 03 |
| Ophthalmology | 04 | 00 | 04 |
| Pediatrics | 01 | 01 | 02 |
| Pharmacology | 02 | 01 | 03 |
| Physiology | 01 | 04 | 05 |
| Plastic Surgery | 02 | 00 | 02 |
| Prev. Oncology | 02 | 00 | 02 |
| Psychiatry | 02 | 02 | 04 |
| Stem Cell | 01 | 02 | 03 |
| TOTAL | 77 | ||
FA: Funds Available | OF: Own Fellowship (CSIR/ICMR/DBT JRF)
š Examination Pattern
Total Qs
70 MCQs
Duration
90 Min
Centre
Delhi/NCR
Marking Scheme
Correct
+1
Wrong
-1/3
Skipped
0
Stages Breakdown
| Stage | Qs | Time | Topic |
|---|---|---|---|
| Stage I | 30 | 40m | Aptitude / Bio-stats / Research Meth. |
| Stage II | 40 | 50m | Subject (MD/MSc Level) |
| Min. Qualifying: 35 Marks (Stage I+II) | |||
Stage III (Dept. Assessment): 3x candidates shortlisted. Carries 20 Marks. Final Rank = Stage I+II + Stage III + Special Weightage.
š Eligibility & Weightage
Medical & Nursing Eligibility +
- MBBS/BDS (min 55%)
- MD/MS/MDS/DM/M.Ch/DNB
- M.Sc Nursing (min 55%)
- Special Weightage: +10 Marks eligible
Non-Medical Eligibility +
- M.Sc/Master’s (2 yr) with min 60%
- OF Seats: Must have JRF (CSIR/UGC/ICMR/DBT/NBHM)
- Special Weightage: +10 Marks if JRF qualified (Jan 24 – Jan 26)
š How to Apply
Applications are accepted online only via the official AIIMS Examination portal.
Go to Application Portal āOfficial Website: www.aiimsexams.ac.in
Official Notification PDF – CLICK HERE TO DOWNLOAD
š¬ Detailed Seat Matrix & Projects
Legend: FA = Funds Available in Project (Salary provided) | OF = Own Fellowship Required (Candidate must have JRF)
*Note: For OF seats, holding a valid Government Fellowship is mandatory in addition to the mentioned qualification.
| Department | Type | Seats | Project Title & Code | Funding Agency | Specific Qualification |
|---|---|---|---|---|---|
| 1. Anaesthesiology | |||||
| Anaesthesiology | FA | 1 | Evaluation of a ‘bundled intervention’ to restore circadian rhythm in critically ill sepsis patients: A randomized controlled trial (1-1796) | ICMR | M.Sc. in Life Sciences/Biochemistry/Biotechnology from recognized University. (Age upto 35 years) |
| 2. Anatomy | |||||
| Anatomy | FA | 1 | A multiomics study for novel biomarkers in exosomes of pancreatic neuroendocrine tumors patients (ANRF-84) | ANRF | M.Sc. Medical Anatomy/Zoology/Pharmacology/Neuroscience/Biomedical Science/Biochemistry/Microbiology from recognized University. (Age upto 30 years) |
| Anatomy | FA | 1 | A quick and cost effective nanotechnology-based visual detection of HPV induced cervical cancer (SERB) | SERB (ANRF) | M.Sc. in Anatomy/Biotechnology/Biochemistry/Nano Sciences from recognized University. (Age upto 30 years) |
| Anatomy | FA | 1 | Cisplatin-encapsulated HPV virion-based targeted delivery vehicle validation (1-1693) | ICMR | M.Sc. in Anatomy/Biotechnology/Biochemistry/Nano Technology/Virology from recognized University. (Qualified any National Level Exam) |
| Anatomy | FA | 1 | Validation of Vionix Spectral Analyzer against ICP-MS, GC-MS and LC-MS (N-2617) | Vionix Biosciences | M.Sc. in Medical Anatomy/Applied Biotechnology/Applied Sciences/Biomedical Sciences from recognized University. (Age upto 35 years) |
| Anatomy | FA | 1 | Unraveling the Biological Age Signature through the Epigenome (BASE) in Temporal Lobe Epilepsy (1-1788) | ICMR | M.Sc. in Anatomy/Biotechnology/Biochemistry/Genetics/Neurosciences from recognized University. (1 year research experience, Age upto 35 years) |
| Anatomy | OF | 1 | A multiomics study for novel biomarkers in exosomes of pancreatic neuroendocrine tumors (ANRF-84) | ANRF | M.Sc. Medical Anatomy/Zoology/Pharmacology/Neuroscience/Biomedical Science/Biochemistry/Microbiology from recognized University. (Age upto 30 years). Own fellowship mandatory. |
| Anatomy | OF | 1 | Unraveling the Biological Age Signature through the Epigenome (BASE) (1-1788) | ICMR | M.Sc. in Anatomy/Biotechnology/Biochemistry/Genetics/Neurosciences from recognized University. (1 year research experience, Age upto 35 years). Own fellowship mandatory. |
| 3. Biochemistry | |||||
| Biochemistry | FA | 1 | Functional characterization of Tumor suppressors p53 and PRB (ANRF-81) | ANRF | M.Sc. / M.Tech in Life Sciences/Genetics/Medical Biotechnology/Biochemistry/Biophysics. (Age upto 35 years) |
| Biochemistry | FA | 1 | Exploring the impact of new endogenous protein derived peptides on restoring tumor microenvironment (ANRF) | ANRF | M.Sc. Biochemistry/Biotechnology/Molecular Biology/Immunology with CSIR NET JRF/LS qualified. (Age upto 28 years) |
| Biochemistry | OF | 1 | Development of CRISPR-based screening and quantitative assays for HBV, HCV, HIV (1-1909) | ICMR | M.Sc. in Biochemistry/Life Sciences/Biotechnology/Microbiology. Own fellowship mandatory. |
| Biochemistry | OF | 1 | Targeting oncogenic signalling of the atypical cadherin FAT1 by small molecules in glioma tumor model (ANRF-80) | ANRF-SERB | M.Sc. in Biochemistry/Life Sciences/Biotechnology/Genetics. Own fellowship mandatory. |
| Biochemistry | OF | 1 | An therapeutic strategy for tackling drug resistant triple negative breast cancer using targeted siRNA (1-1850) | ICMR | M.Sc. in Biochemistry/Life Sciences/Biotechnology/Genetics. Own fellowship mandatory. |
| Biochemistry | OF | 1 | Developing DdpMPYPEPhU as a multitargeted drug for breast cancer using AI-guided optimisation (1-1906) | ICMR | M.Sc. in Biochemistry/Life Sciences/Biotechnology/Genetics. Own fellowship mandatory. |
| Biochemistry | OF | 1 | Elucidating the role of exosomal microRNAs in immunomodulation of yĆ T cells in pancreatic ductal adenocarcinoma (ANRF-81) | ANRF | M.Sc./M.Tech in Life Sciences/Genetics/Medical Biotechnology/Biochemistry/Biophysics. Own fellowship mandatory. |
| Biochemistry | OF | 1 | Delineating Immune Checkpoint Markers and Immune Signatures in Acute Myeloid Leukemia (DHR-1894) | DHR | M.Sc./M.Tech in Life Sciences/Genetics/Medical Biotechnology/Biochemistry/Biophysics/Immunology/Microbiology. Own fellowship mandatory. |
| 4. Biophysics | |||||
| Biophysics | FA | 1 | Preclinical Assessment of a novel Tyrosine Kinase Inhibitor, KKI04 for Non-Small Cell Lung Cancer (1-1755) | ICMR | M.Sc. in Biophysics/Biotechnology with 02 years research experience in animal handling/cell culture. (Age upto 30 years) |
| Biophysics | FA | 1 | Deciphering the contribution of proestrous-estrous transition to seizure susceptibility in epilepsy (BT-2223) | DBT | M.Sc. in Biophysics/Neuroscience with 02 years research experience. (Age upto 35 years) |
| Biophysics | OF | 1 | Integrative Proteomics and Metabolomics Analysis of Plasma and Exosomes for NSCLC (1-1719) | ICMR | M.Sc. in Biophysics/Biotechnology. Own fellowship mandatory. |
| Biophysics | OF | 1 | Preclinical Assessment of a novel Tyrosine Kinase Inhibitor, KKI04 (1-1755) | ICMR | M.Sc. in Biophysics/Biotechnology. Own fellowship mandatory. |
| Biophysics | OF | 1 | Structural Insights into Mycobacterium tuberculosis Multidrug Transporter (BT-2221) | DBT | M.Sc./M.Tech in Biophysics/Biotechnology/Life Sciences. Own fellowship mandatory. |
| 5. Biotechnology | |||||
| Biotechnology | OF | 1 | Therapeutic targeting of Cell death and efferocytosis pathways as a novel host-directed therapy in tuberculosis (1-1891) | ICMR | M.Sc. in Life Sciences/Biochemistry/Microbiology/Immunology/Genetics/Biotechnology. Own fellowship mandatory. |
| 6. Cardiology | |||||
| Cardiology | FA | 1 | Cardio Watch-India: Safeguarding Young Hearts through early Multi-Biomarker Precision Diagnostics (1-1838) | ICMR | M.Sc. in Biochemistry/Biotechnology from recognized University. (Age upto 35 years) |
| 7. Dermatology & Venereology | |||||
| Dermatology | FA | 1 | A multicenter global clinical study to assess the efficacy of a topical cream for atopic dermatitis (N-2541) | Clinical Research | M.Sc. in Life Sciences/Biotechnology/Clinical Research. |
| 8. Emergency Medicine (JPNATC) | |||||
| Emergency Med | OF | 1 | Impact evaluation of a surgery capacity building intervention in rural India (N-2558) | UGC | M.Sc./M.A in Life Sciences/Social Sciences/Public Health. Own fellowship mandatory. |
| 9. Endocrinology & Metabolism | |||||
| Endocrinology | FA | 1 | An integrative approach using genomics and tissue proteomics in Pheochromocytomas and Paragangliomas (1-1819) | ICMR | M.Sc. in Biochemistry/Biotechnology/Genetics/Life Sciences with 02 years research experience. (Age upto 35 years) |
| Endocrinology | OF | 1 | An integrative approach using genomics and tissue proteomics in Pheochromocytomas and Paragangliomas (1-1819) | ICMR | M.Sc. in Biochemistry/Biotechnology/Genetics. Own fellowship mandatory. |
| 10. Forensic Medicine and Toxicology | |||||
| Forensic Med | FA | 1 | Building Resources for the Diversification of Genetic Data on Suicide Death (N-2459) | NIMH USA | M.Sc. in Forensic Science/Toxicology/Genetics/Biotechnology. (Age upto 35 years) |
| Forensic Med | OF | 1 | Building Resources for the Diversification of Genetic Data on Suicide Death (N-2459) | NIMH USA | M.Sc. in Forensic Science/Toxicology/Genetics/Biotechnology. Own fellowship mandatory. |
| 11. Gastroenterology & HNU | |||||
| Gastroenterology | FA | 1 | Hypoxia, angiogenesis and stemness markers predicting outcome of locoregional hepatocellular carcinoma (1-1629) | ICMR | M.Sc. Medical Anatomy/Life Science/Biochemistry/Biotechnology with 02 years research experience. (Age upto 35 years) |
| Gastroenterology | FA | 1 | Chronic pancreatitis induces mitochondrial dysfunction and proteostasis in skeletal muscle (1-1680) | ICMR | M.Sc. Medical Anatomy/Life Science/Biochemistry/Biotechnology with 02 years research experience. (Age upto 35 years) |
| Gastroenterology | OF | 1 | Hypoxia, angiogenesis and stemness markers predicting outcome of locoregional hepatocellular carcinoma (1-1629) | ICMR | M.Sc. Medical Anatomy/Life Science/Biochemistry/Biotechnology. Own fellowship mandatory. |
| 12. Laboratory Medicine | |||||
| Lab Medicine | FA | 1 | A Two Arm Longitudinal Randomized Control Trial to Evaluate the Bone Protective Role of an Ayurveda Formulation (1-1862) | AYUSH-ICMR | M.Sc. in Life Sciences/Biochemistry/Biotechnology/Ayush relevant degree. |
| Lab Medicine | OF | 1 | A Two Arm Longitudinal Randomized Control Trial to Evaluate the Bone Protective Role of an Ayurveda Formulation (1-1862) | AYUSH-ICMR | M.Sc. in Life Sciences/Biochemistry/Biotechnology/Ayush relevant degree. Own fellowship mandatory. |
| 13. Laboratory Oncology (Dr. BRA IRCH) | |||||
| Lab Oncology | OF | 1 | To evaluate the diagnostic accuracy of Smart Sure HPV-HR assays and GeneNAT-300 Real-time PCR system (N-2582) | Genetix Biotech | M.Sc. in Life Sciences/Biotechnology/Biochemistry/Microbiology. Own fellowship mandatory. |
| Lab Oncology | OF | 1 | A prospective study to elucidate genetics, clinical and molecular factors in gall bladder carcinoma (1-1799) | Cancer Foundation | M.Sc. in Life Sciences/Biotechnology/Biochemistry/Microbiology. Own fellowship mandatory. |
| 14. Medical Oncology (Dr. BRA IRCH) | |||||
| Med Oncology | OF | 1 | Assessing the theranostic capabilities of the Aurora-A/TPX2 complex in Gallbladder cancer (1-1806) | ICMR | M.Sc. in Biotechnology/Life Sciences/Biochemistry/Genetics/Zoology. Own fellowship mandatory. |
| Med Oncology | OF | 1 | Characterization of Novel anti BCMA Antibody Drug conjugate as a immunotherapeutic agent in Multiple Myeloma (1-1790) | ICMR | M.Sc. in Biotechnology/Life Sciences/Biochemistry/Genetics/Zoology. Own fellowship mandatory. |
| Med Oncology | OF | 1 | Uncovering the Impact of tRNA Modifications in Acute Myeloid Leukemia (N-2530) | Genes2Me Pvt Ltd | M.Sc. in Biotechnology/Life Sciences/Biochemistry/Genetics/Zoology. Own fellowship mandatory. |
| 15. Microbiology | |||||
| Microbiology | FA | 1 | UTI-Diag: Reducing the burden of antimicrobial resistance in urinary tract infection (N-2636) | Research Council Norway | M.Sc. in Microbiology/Bioinformatics/Biotechnology. (Age upto 30 years) |
| Microbiology | OF | 1 | CRISPR/Cas9 targeting virulence and resistance genes of uropathogenic Escherichia coli (1-1816) | ICMR | M.Sc. in Microbiology/Biotechnology/Life Sciences. Own fellowship mandatory. |
| Microbiology | OF | 1 | Validation of blood based transcriptional biomarkers for diagnosis of extrapulmonary tuberculosis (A-IGIB-7) | CSIR-IGIB | M.Sc. in Microbiology/Biotechnology/Life Sciences. Own fellowship mandatory. |
| 16. Neuro-Biochemistry (NSC) | |||||
| Neuro-Biochem | OF | 1 | Boron based therapeutics against RNA viruses and associated post-infection arthritis in chikungunya (1-1881) | ICMR | M.Sc. in Biochemistry/Life Sciences/Biotechnology/Genetics. Own fellowship mandatory. |
| 17. Neurology | |||||
| Neurology | FA | 1 | Boron based therapeutics against RNA viruses – a preclinical evaluation (1-1821) | ICMR | M.Sc. in Genetics/Bioinformatics/Biochemistry/Biotechnology. (Age upto 35 years) |
| Neurology | FA | 1 | SonoSpeech: Towards Wearable Ultrasound-based Assessment of Speech Disorders (N-2632) | Translational Research | M.Tech in Biomedical Engineering/E&C/CS/IT OR M.Sc. in Biomedical Science/Biophysics. (Age upto 35 years) |
| Neurology | OF | 1 | PRKN heterozygosity and association to Parkinson’s Disease (GP2) | GP2 (Queen Mary Univ) | M.Sc. in Genetics/Bioinformatics/Life Sciences. Own fellowship mandatory. |
| 18. Neuropathology (NSC) | |||||
| Neuropathology | FA | 1 | Transforming CNS Tumor Care: Harnessing Histopathological Data, Multi-omics, and AI (1-1764) | ICMR | M.Sc. in Life Sciences/Biotechnology/Genetics/Biochemistry. (Age upto 35 years) |
| 19. Nuclear Magnetic Resonance (NMR) | |||||
| NMR | OF | 1 | An integrated metabolomics and lipidomics approach for identifying biomarkers for Non-Small-Cell-Lung Cancer (1-1687) | ICMR | M.Sc./M.Tech in Chemistry/Physics/Life Sciences/Biotechnology. Own fellowship mandatory. |
| 20. Ophthalmology (Dr. R.P. Centre) | |||||
| Ophthalmology | FA | 1 | Development and standardization of corneal cross-linking device for corneal infections (BT-2239) | BIRAC | M.Sc. in Biotechnology/Biochemistry/Optometry/Life Sciences. (Age upto 35 years) |
| Ophthalmology | FA | 1 | Phase IV study to evaluate Pilocarpine Hydrochloride ophthalmic solution for presbyopia (N-2624) | Biosphere Clinical | M.Sc. in Biotechnology/Biochemistry/Optometry/Life Sciences. (Age upto 35 years) |
| Ophthalmology | FA | 1 | Safety and Efficacy of Supra Phob Regen Trifocal IOL of Appasamy Ocular Devices (N-2545) | Appasamy Pvt Ltd | M.Sc. in Biotechnology/Biochemistry/Optometry/Life Sciences. (Age upto 35 years) |
| Ophthalmology | FA | 1 | Assessment of functional vision and role of therapy in children with cortical visual impairment (1-1867) | ICMR | M.Sc. in Biotechnology/Biochemistry/Optometry/Life Sciences. (Age upto 35 years) |
| 21. Oral Pathology & Microbiology (CDER) | |||||
| Oral Pathology | FA | 1 | Efficacy of Allogenic Mesenchymal Stem Cells in Patients with Oral Submucous Fibrosis (1-1910) | ICMR | MDS in Oral Pathology/M.Sc. in Biotechnology/Life Sciences. (Age upto 35 years) |
| 22. Pathology | |||||
| Pathology | OF | 1 | Multiplexed spatially resolved analysis of protein signature of the invasive front of Oral Squamous Cell Carcinoma (1-1702) | ICMR | M.Sc. in Life Sciences/Biotechnology/Biochemistry. Own fellowship mandatory. |
| 23. Pediatrics | |||||
| Pediatrics | FA | 1 | Clinical Relevance of Mitochondrial Signaling in Pediatric Intraocular Malignancy (ANRF-79) | ANRF | M.Sc. in Life Sciences/Biochemistry/Biotechnology/Genetics. (Age upto 35 years) |
| Pediatrics | OF | 1 | Clinical Relevance of Mitochondrial Signaling in Pediatric Intraocular Malignancy (ANRF-79) | ANRF | M.Sc. in Life Sciences/Biochemistry/Biotechnology/Genetics. Own fellowship mandatory. |
| 24. Pharmacology | |||||
| Pharmacology | FA | 1 | Effect of Selected Unani formulation on oxidative stress in patients with type 2 diabetes mellitus (AY-2637) | CCRUM | M.Pharm in Pharmacology/M.Sc. in Pharmacology/Biotechnology/Life Sciences. (Age upto 35 years) |
| Pharmacology | FA | 1 | Evaluation of Crotalus horridus, Carica papaya, and Lachesis Formulations in Thrombocytopenia (N-2633) | CCRH (Ayush) | M.Pharm in Pharmacology/M.Sc. in Pharmacology/Biotechnology/Life Sciences. (Age upto 35 years) |
| Pharmacology | OF | 1 | Evaluation of Crotalus horridus, Carica papaya, and Lachesis Formulations in Thrombocytopenia (N-2633) | CCRH (Ayush) | M.Pharm in Pharmacology/M.Sc. in Pharmacology/Biotechnology/Life Sciences. Own fellowship mandatory. |
| 25. Physiology | |||||
| Physiology | FA | 1 | Clinical determinants of the cognitive sequelae of chemotherapy in breast cancer (1-1915) | ICMR | M.Sc. in Physiology/Life Sciences/Neuroscience/Biotechnology. (Age upto 35 years) |
| Physiology | OF | 1 | Clinical determinants of the cognitive sequelae of chemotherapy in breast cancer (1-1915) | ICMR | M.Sc. in Physiology/Life Sciences/Neuroscience/Biotechnology. Own fellowship mandatory. |
| Physiology | OF | 1 | Effect of nostril breathing patterns in the patients of Major Depressive Disorder (1-1674) | ICMR | M.Sc. in Physiology/Life Sciences/Neuroscience/Yoga Therapy. Own fellowship mandatory. |
| Physiology | OF | 1 | Immune signatures and role of neutrophils in pathophysiology of post tuberculosis pulmonary sequelae (1-1651) | ICMR | M.Sc. in Physiology/Life Sciences/Biotechnology/Immunology. Own fellowship mandatory. |
| Physiology | OF | 1 | Developing a combinatorial bio-marker based on encephalic and metabolome profiles to differentiate seizures (1-1708) | ICMR | M.Sc. in Physiology/Life Sciences/Neuroscience/Biotechnology. Own fellowship mandatory. |
| 26. Plastic, Reconstructive & Burns Surgery | |||||
| Plastic Surgery | FA | 1 | Pre-compliance analysis and clinical tolerability study of biomimetic silk fibroin based wound healing dressing (1-1826) | ICMR | M.Sc. in Biotechnology/Life Sciences/Biochemistry/Microbiology. (Age upto 35 years) |
| Plastic Surgery | FA | 1 | Randomized Controlled Trial on effect of Indigenous Cows Ghrita and Jatyadi Ghrita on wound healing (N-2354) | CCRAS | BAMS/M.Sc. in Life Sciences/Biotechnology/Biochemistry. (Age upto 35 years) |
| 27. Preventive Oncology | |||||
| Preventive Onc | FA | 1 | Implementation Research to enhance screening, early diagnosis and initiation of treatment for cancers (1-1769) | ICMR | M.Sc. in Life Sciences/Public Health/Epidemiology/Biotechnology/Biochemistry. (Age upto 35 years) |
| Preventive Onc | FA | 1 | Implementation Research to enhance screening, early diagnosis and initiation of treatment for cancers (1-1769) | ICMR | M.Sc. in Life Sciences/Public Health/Epidemiology/Biotechnology/Biochemistry. (Age upto 35 years) |
| 28. Preventive Oncology (NCI Jhajjar) | |||||
| Preventive Onc | FA | 1 | Screening for risk factors and precancerous lesions of head & neck and prostate cancers (N-2221) | Bayer Pharma | M.Sc. in Life Sciences/Public Health/Epidemiology/Biotechnology/Biochemistry. (Age upto 35 years) |
| Preventive Onc | FA | 1 | Screening for risk factors and precancerous lesions of head & neck and prostate cancers (N-2221) | Bayer Pharma | M.Sc. in Life Sciences/Public Health/Epidemiology/Biotechnology/Biochemistry. (Age upto 35 years) |
| 29. Psychiatry | |||||
| Psychiatry | FA | 1 | A study to develop and evaluate a manual-assisted tailored intervention for cardiovascular risk in depression (1-1738) | ICMR | M.A./M.Sc. in Psychology/Clinical Psychology with 02 years research experience. (Age upto 35 years) |
| Psychiatry | FA | 1 | School-based transdiagnostic trauma-focused CBT for adolescents with depression (1-1722) | ICMR | M.A./M.Sc. in Psychology/Clinical Psychology with 02 years research experience. (Age upto 35 years) |
| Psychiatry | OF | 1 | School-based transdiagnostic trauma-focused CBT for adolescents with depression (1-1722) | ICMR | M.A./M.Sc. in Psychology/Clinical Psychology. Own fellowship mandatory. |
| Psychiatry | OF | 1 | Preconception integrated healthcare for women: development of a perceived health risk assessment tool (DHR-1699) | DHR | M.A./M.Sc. in Psychology/Clinical Psychology/Public Health/Social Work. Own fellowship mandatory. |
| 30. Stem Cell | |||||
| Stem Cell | FA | 1 | Functionalized 3D Tracheal Analogue for multivariate translational application (1-1762) | ICMR | M.Sc./M.Tech in Life Sciences/Biochemistry/Biotechnology/Zoology. (Age upto 30 years) |
| Stem Cell | OF | 1 | Functionalized 3D Tracheal Analogue for multivariate translational application (1-1762) | ICMR | M.Sc./M.Tech in Life Sciences/Biochemistry/Biotechnology/Zoology. Own fellowship mandatory. |
| Stem Cell | OF | 1 | Novel Bioink-Based 3D Printed Organoid As A High Throughput Platform For Animal-Free Drug Screening (DHR-1723) | ICMR-DHR | M.Sc./M.Tech in Life Sciences/Biochemistry/Biotechnology/Zoology. Own fellowship mandatory. |